Spark Therapeutics (ONCE) Receives a Hold from Mizuho Securities

In a report released today, Difei Yang from Mizuho Securities reiterated a Hold rating on Spark Therapeutics (ONCE), with a price target of $114.50. The company’s shares opened today at $100.40.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 5.0% and a 39.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Audentes Therapeutics.

Spark Therapeutics has an analyst consensus of Hold, with a price target consensus of $114.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $114.20 and a one-year low of $34.53. Currently, Spark Therapeutics has an average volume of 495.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases.